# FDA Finalizes Biosimilar Manufacturing Guidance

On October 13, 2026, the FDA finalized nonbinding Q&A guidance explaining what applicants should provide when reporting postapproval manufacturing changes to licensed biosimilar and interchangeable biosimilar products under section 351(k). The guidance aligns recommendations with ICH Q5E, clarifies the use of comparative analytical assessment data and evidence for new dosage forms or strengths, and withdraws the prior related Q&A. It is a regulatory development rather than a procurement announcement, but it may inform work performed by manufacturers and contractors supporting biosimilar manufacturing, quality, and regulatory submissions.

- Manufacturers and service providers can use the guidance to align submission-support and quality services with FDA’s stated recommendations; the guidance is nonbinding and does not itself create a procurement requirement.
- Contractors supporting biosimilar applicants should account for the clarified evidence expectations, including comparative analytical assessments and support for new dosage forms or strengths, when scoping relevant services.
- The withdrawal of the prior Q&A means organizations relying on it should refer to the finalized guidance for the FDA’s current recommendations.

**Jurisdictions:** federal
**Industries:** Healthcare
**Topics:** Regulatory Compliance
**Published:** October 20, 2026

### Government Entities
- U.S. Food and Drug Administration (FDA)

### Sources
- [FDA Finalizes Q&A Guidance on Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products | Goodwin - JDSupra](https://www.jdsupra.com/legalnews/fda-finalizes-q-a-guidance-on-1887705) - JD Supra